mercredi 23 octobre 2019

Onco Actu du 23 octobre 2019


1.1 BIOLOGIE - GÉNOME



At Annual Plenary Meeting, GA4GH Unveils New Standards for Genomic Data, Workflow Sharing [Genome Web]











1.4 BIOLOGIE - TECHNOS, MODÈLES



The breast cancer ‘avatar’ mice that could help personalise treatment [Cancer Research UK]










David Liu unveils newest advancement in CRISPR tech: Prime editing [EndPoints]











3.1 PRÉVENTION - TABAC



FDA grants first-ever modified risk orders to eight smokeless tobacco products [FDA]











3.1.1 PRÉVENTION - TABAC - E-CIGS



South Korea warns of 'serious risk' from vaping, considers sales ban [Reuters]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Precision Medicine: State of affairs, strategic insight, trends, and predictions for 2020 all revealed in Diaceutics’ 2019 Pharma Precision Medicine Readiness Report [Diaceutics]











Report Says Many Precision Drugs Will Launch in Coming Years But Unclear if They Will Reach Patients [Genome Web]










4.1 DÉP., DIAG. & PRONO. - PROSTATE



Worcester Polytechnic Institute Researcher is Creating a Safer, More Accurate Way to Detect Prostate Cancer [WPI]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Sequencing Plays Role in Treating High Risk Pediatric Brain Tumors [University of Michigan]











4.9 DÉP., DIAG. & PRONO. - SEIN



Aggressive Form of Breast Cancer Influenced by Dual Action of Genes and RNA [Georgetown University]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high bar [Fierce Pharma]










Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study [EndPoints]











Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Reuters]











CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer [BMS]











5.2.6 PHARMA - BIOTECH



Intrepida Bio uncloaks with $9.5M and anti-BAG3 cancer programs from Italy [Fierce Biotech]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



EMA Recommends Refusal of the Marketing Authorisation for Quizartinib [ESMO]











5.5 ASCO



Patients With Chemotherapy-Induced Peripheral Neuropathy Experience Pain Reduction in a Pilot Study of Oncology Massage Treatment [ASCO]











Cancer Pain Predicted by Lower Anxiety and Depression, Higher Social Support [ASCO]











6.7.2 APPLIS



Roche launches NAVIFY Guidelines app to help clinicians easily access, personalise and document latest guidance for patients with the most common cancers [NCCN]











6.8 COMMUNICATION



How one bit of medical jargon fuels public confusion about cancer treatments [Health News Review]